CSIMarket

Amgen Inc   (AMGN)
Other Ticker:  
 
 
Price: $243.8700 $0.47 0.193%
Day's High: $245.11 Week Perf: 1.31 %
Day's Low: $ 241.16 30 Day Perf: -4 %
Volume (M): 2,415 52 Wk High: $ 258.45
Volume (M$): $ 588,824 52 Wk Avg: $228.44
Open: $241.24 52 Wk Low: $198.64



 Market Capitalization (Millions $) 134,372
 Shares Outstanding (Millions) 551
 Employees 24,300
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 5,723
 Cash Flow (TTM) (Millions $) 416
 Capital Exp. (TTM) (Millions $) 904

Amgen Inc
Amgen Inc. Is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. On July 15, 2002, Amgen acquired all of the outstanding common stock of Immunex Corporation (“Immunex”) for stock and cash valued at $17.8 billion in a transaction accounted for as a business combination. Immunex was a leading biotechnology company dedicated to developing immune system science to protect human health. The acquisition has enhanced Amgen’s strategic position within the biotechnology industry by strengthening and diversifying its (1) product base and product pipeline in key therapeutic areas, and (2) discovery research capabilities in proteins and antibodies.

The Company markets human therapeutic products in the areas of hematology, oncology, and inflammation. The Company’s key products include EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim), and ENBREL® (etanercept), which is marketed under a co-promotion agreement with Wyeth. The Company’s other products include Kineret® (anakinra) and Stemgen® (Ancestim).

EPOGEN® and Aranesp® stimulate the production of red blood cells. EPOGEN® is marketed in the United States for the treatment of anemia associated with chronic renal failure in patients on dialysis. Aranesp® is marketed in the United States, most countries in Europe, Australia, and New Zealand for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. Aranesp® is also marketed in the United States for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. Aranesp® is marketed in Europe for the treatment of anemia in adult cancer patients with solid tumors receiving chemotherapy and for the treatment of chemotherapy-induced anemia in adult patients with non-myeloid malignancies.

Neulasta® and NEUPOGEN® selectively stimulate the production of neutrophils, one type of white blood cell. Neulasta® is marketed in the United States to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta® is marketed in most countries in Europe for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients with cytotoxic chemotherapy for malignancy. NEUPOGEN® is marketed in the United States, certain countries in Europe, Canada, and Australia for use in decreasing the incidence of infection in patients undergoing myelosuppressive chemotherapy. In addition, NEUPOGEN® is marketed in most of these countries for use in increasing neutrophil counts in various other treatment modalities.

ENBREL® blocks the biologic activity of tumor necrosis factor (“TNF”) by competitively inhibiting TNF, a substance induced in response to inflammatory and immunological responses. ENBREL® is marketed in the United States for reducing the signs and symptoms, improving physical function, and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis; and for reducing the signs and symptoms and inhibiting the progression of structural damage in patients with psoriatic arthritis. In addition, ENBREL is approved for reducing the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying medicines; and to treat the signs and symptoms in patients with active ankylosing spondylitis.

The Company maintains a sales and marketing force in the United States, Europe, Canada, Australia, and New Zealand. In addition, Amgen has entered into licensing and/or co-promotion agreements to market certain of its products including Aranesp®, Neulasta®, NEUPOGEN®, and ENBREL® in certain geographic areas outside of the United States.

The Company focuses its research and development (“R&D”) efforts on human therapeutics delivered in the form of proteins, monoclonal antibodies, and small molecules in the areas of hematology, oncology, inflammation, metabolic and bone disorders, and neuroscience. The Company has research facilities in the United States, and has clinical development staff in the United States, Europe, Canada, Australia, and Japan. In addition to internal R&D efforts, the Company has acquired certain product and technology rights and has established R&D collaborations.

The Company manufactures EPOGEN®, Aranesp®, Neulasta®, NEUPOGEN®, and ENBREL®. Amgen operates commercial manufacturing facilities located in the United States, Puerto Rico, and a packaging and distribution center in the Netherlands. Additional supply of ENBREL® is produced by our contract manufacturer, Boehringer Ingelheim Pharma KG (“BI Pharma”).

Any products or technologies that are directly or indirectly successful in addressing anemia could negatively impact the market for EPOGEN® and Aranesp®. Aranesp® directly competes with other currently marketed products which treat anemia, including EPOGEN® and the recombinant human erythropoietin product marketed by Johnson & Johnson. Aventis Pharmaceuticals Inc. (“Aventis”) is developing gene-activated erythropoietin for the treatment of anemia. Baxter International Inc. (“Baxter”) is developing epoetin omega for the treatment of anemia. Roche is developing a pegylated erythropoietin product for the treatment of anemia.

Any products or technologies that are directly or indirectly successful in addressing anemia associated with chemotherapy could negatively impact the market for Aranesp®. In the United States, Aranesp® directly competes with other currently marketed products which treat anemia associated with chemotherapy, including the recombinant human erythropoietin product marketed by Johnson & Johnson. In Europe, Aranesp® directly competes with other erythropoietin products marketed by Ortho Biotech/Janssen-Cilag/Johnson & Johnson and Roche in the oncology setting.

Chugai Pharmaceuticals Co., Ltd. (“Chugai”) markets a G-CSF product in Japan as an adjunct to chemotherapy and as a treatment for bone marrow transplant (“BMT”) patients. Chugai and Aventis market a G-CSF product in certain EU countries as an adjunct to chemotherapy and as a treatment in BMT settings. Chugai, through its licensee, AMRAD, markets this G-CSF product in Australia as an adjunct to chemotherapy and as a treatment for BMT patients. Under an agreement with Amgen, Chugai is precluded from selling its G-CSF product in the United States, Canada, and Mexico.

ENBREL® and PEG-sTNF-R1 could face competition in some circumstances from a number of companies developing or marketing rheumatoid arthritis and psoriatic arthritis treatments. Current anti-arthritic treatments include generic methotrexate and other products marketed by, among others, Centocor, Inc./Johnson & Johnson, Abbott Laboratories (“Abbott”), Merck, Pfizer, Novartis, Aventis, and Sanofi-Synthélabo. In addition, a number of companies have cytokine inhibitors in development including GlaxoSmithKline, Pfizer, and Taisho Pharmaceutical Co., Ltd. Amgen is currently developing ENBREL® for the treatment of psoriasis. If ENBREL® is approved for this indication, it may compete with products marketed by Biogen, Genentech, and Johnson & Johnson.

SensiparTM could face competition from products currently marketed by Abbott, Bone Care International, Inc., Genzyme Corporation, and Roche which treat secondary HPT. In addition, another product to treat HPT is currently being developed by Chugai.

The GDNF program could face competition from a deep brain stimulation device currently marketed by Medtronic Inc.



   Company Address: One Amgen Center Drive Thousand Oaks 91320 CA
   Company Phone Number: 447-1000   Stock Exchange / Ticker: NASDAQ AMGN
   AMGN is expected to report next financial results on August 02, 2022.


Customers Net Income grew by AMGN's Customers Net Profit Margin fell to

2.59 %

4.49 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        2.99% 
BIIB        5.78% 
ACT        1.46% 
LLY        3.51% 
BMY        0.84% 
MRK        5.34% 
• View Complete Report
   



Iclick Interactive Asia Group Limited

Despite Surge in Sales Profitability not Reached

Iclick Interactive Asia Group Limited announced in the financial fourth quarter of 2021 surge in Sales by 20.79% to $307.70 millions from the same quarter a year ago, but it has lost money at $-0.28 per share.

China Life Insurance Company Limited

Profits surpass Sales

Sale of $116 million assets, inflates fiscal time-frame ending Dec 31 2021 eps to $0.27

Relx Plc

Double Digit EPS Growth with Modest Revenue Increase

Relx Plc achieved double digit earnings growth on moderate Sales increase in the financial interval ending Dec 31 2021, where income increased by 19.94 % to $0.76 per share, Sales grew modestly by 1.88% to $7.24 billions from the same quarter a year ago.

Vnet Group inc

Vnet Group Inc announced fourth quarter of 2021 operating profit of $3.345 millions

Company lost money at $-0.06 per share in the fourth quarter of 2021, although its Sales surged by 31.24% to $971.32 millions from the same quarter a year ago.

Golden Ocean Group Limited

Golden Ocean Group Limited declared fiscal interval ending Dec 31 2021 operating income of $513.608 millions

In the fiscal interval ending Dec 31 2021 Golden Ocean Group Limited earnings turn positive of $2.73 per share compared to $-0.96 a year ago and from $0.00 per share from the previous quarter.






 

Amgen Inc 's Segments
 
United States
 Segment    80.22 % of total Revenue
International
 Segment    19.78 % of total Revenue
EPOGEN TM
 Segment    17.73 % of total Revenue
Aranesp
 Segment    8.94 % of total Revenue
Prolia
 Segment    11.6 % of total Revenue
NEUPOGEN
 Segment    5.15 % of total Revenue
Nplate
 Segment    2.48 % of total Revenue
Neulasta
 Segment    42.11 % of total Revenue
XGEVA
 Segment    6.85 % of total Revenue
ENBREL
 Segment    26.45 % of total Revenue
Vectibix
 Segment    0.98 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Amgen Inc does not provide revenue guidance.

Earnings Outlook
Golden Ocean Group Limited does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 76.74 %
International 23.26 %


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PLNT's Profile

Stock Price

PLNT's Financials

Business Description

Fundamentals

Charts & Quotes

PLNT's News

Suppliers

PLNT's Competitors

Customers & Markets

Economic Indicators

PLNT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071